- Home
- BTMD vs IMA Comparison
BTMD vs IMA Comparison
Compare BTMD & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | IMA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 54.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTMD | IMA |
|---|---|---|
| Price | $2.22 | $5.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $2.83 | ★ $16.00 |
| AVG Volume (30 Days) | 303.3K | ★ 376.1K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $192,219,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $3.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $3.94 |
| 52 Week High | $4.75 | $17.50 |
Technical Indicators
Market Signals| Indicator | BTMD | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 69.22 | 56.12 |
| Support Level | $2.02 | $5.52 |
| Resistance Level | $2.79 | $7.04 |
| Average True Range (ATR) | 0.15 | 0.44 |
| MACD | 0.08 | 0.14 |
| Stochastic Oscillator | 85.39 | 68.29 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.